Feasibility of <scp>CBCT</scp>‐based dose with a patient‐specific stepwise <scp>HU</scp>‐to‐density curve to determine time of replanning

Shifeng Chen, Quynh‐Thu Le, Y. D. Mutaf, Wei Lü, E.m. Nichols, Byong Yong Yi, T. Leven, K Prado, W DˈSouzaJournal of Applied Clinical Medical Physics 2017 · DOI

TL;DR

This paper demonstrates that cone-beam CT (CBCT) can be used for accurate dose calculations in radiation therapy, comparable to traditional CT scans. This opens the door for using CBCT-based dosimetry to help clinicians decide when to replan a patient's treatment during therapy, potentially improving outcomes and reducing costs.

What Problem Does This Paper Address?

Adaptive radiotherapy, where treatment plans are adjusted during the course of therapy, is crucial for optimizing outcomes, especially for patients whose anatomy changes significantly (e.g., due to weight loss or tumor shrinkage). However, a major challenge is knowing when to replan. Clinicians often rely on experience, lacking objective tools to predict substantial dosimetric changes. While CBCT is widely available for patient positioning, its potential for dose calculation has been recognized but hindered by uncertainties in converting CBCT's Hounsfield Units (HU) to electron density. This paper addresses this by investigating the accuracy of CBCT-based dose calculations using a novel patient-specific HU-to-density curve and exploring its feasibility for guiding replanning decisions.

Methods

The core innovation lies in the use of a patient-specific stepwise HU-to-density curve. Unlike standard CT-based planning which uses a single calibration curve, this method converts CBCT HUs into six material classes (air, lung, adipose, tissue, cartilage/bone, and other high-density material). The HU thresholds for these classes were adjusted for each patient to best match known material types, effectively creating a personalized density map from the CBCT images.

Dose calculations were then performed on these CBCT-derived density maps using the RayStation treatment planning system. The accuracy of these CBCT-based dose calculations was compared against dose calculations performed on the original planning CT scans. Key dosimetric parameters like PTV mean dose, D2% (near-maximum dose), D95%, D98% (near-minimum dose), and V95% (volume receiving 95% of prescription dose) were analyzed. Additionally, a gamma analysis with a 3%/3 mm criterion was used to assess dose distribution agreement across different dose levels (high, medium, and low).

To evaluate the feasibility for replanning, the study retrospectively analyzed 12 head and neck cancer patients whose plans had previously been revised. CBCT-based dose calculations were performed on their CBCT images, and the predicted changes in PTV D2% were compared to changes observed on rescanned CT images (considered the ground truth).

Datasets

The study utilized two datasets:

  1. 40 patients with four different disease sites (10 head and neck, 10 lung, 10 pancreas, 10 pelvis) who underwent IMRT or VMAT. For each patient, both planning CT and CBCT images were used. This dataset was used to assess the accuracy of CBCT-based dose calculations.
  2. 12 additional head and neck cancer patients whose plans had been previously revised due to anatomical changes. CBCT images acquired within 3 days of rescanned CT images were available for these patients. This dataset was used to evaluate the feasibility of using CBCT-based dosimetry for guiding replanning decisions.

Key Insights and Ideas

  • Personalized Density Mapping is Key: The patient-specific stepwise HU-to-density curve is crucial for overcoming the inherent uncertainties in CBCT HU values, which can vary due to scatter and other factors. This approach allows for more accurate density assignment than generic curves.
  • CBCT Dose Accuracy is Comparable to CT: The study demonstrates that CBCT-based dose calculations, when performed with this patient-specific method, achieve accuracy comparable to traditional CT-based calculations. This is a significant finding, as it validates CBCT as a viable tool for dose assessment.
  • Potential to Avoid Unnecessary Replanning: The most impactful insight is the potential for CBCT-based dosimetry to guide replanning decisions. By quantitatively assessing dosimetric changes, clinicians may be able to avoid unnecessary replanning procedures, leading to reduced treatment delays and costs.
  • D2% as a Sensitive Indicator: The study highlights PTV D2% (near-maximum dose) as a particularly sensitive parameter for detecting dosimetric changes, especially in cases of weight loss.

Key Results

  • Dose-Volume Parameter Agreement: For all disease sites, the differences in PTV dose-volume parameters between CBCT-based and CT-based plans were small, with mean differences for mean dose, D2%, D95%, D98%, and V95% all within ±1.1% (mean ± SD).
  • Gamma Analysis Success: Gamma analysis (3%/3 mm criterion) showed high passing rates: 99.0% ± 1.9% for high-dose zones, 97.6% ± 4.4% for medium-dose zones, and 95.3% ± 6.0% for low-dose zones across all patients. This indicates excellent agreement in dose distribution.
  • Correlation for Replanning: In the 12 HN patients, CBCT-based predicted changes in PTV D2% were highly correlated with changes observed on rescanned CT (Pearson linear correlation coefficient = 0.93, P < 0.001).
  • Replanning Avoidance: Using a 3% change in D2% as a replanning criterion, 7 out of 12 patients could have potentially avoided replanning procedures.

Limitations and Future Work

  • Geometric Changes: The authors acknowledge that while efforts were made to minimize geometric differences, small variations between planning CT and CBCT might still exist. These could contribute to dosimetric differences, and without them, agreement would likely improve.
  • Clinical Decision Making: The study focuses on the technical feasibility of CBCT-based dosimetry for guiding replanning. The actual clinical decision-making process for when to replan, and the specific criteria to use, are complex and beyond the scope of this paper. Further investigation into clinical guidelines for these criteria is needed.
  • Specific OAR Doses: While PTV parameters were used for replanning feasibility, the authors note that specific organ-at-risk (OAR) doses might also be used to determine replanning time, depending on the clinical scenario.
  • Future Work: The authors suggest that further investigation into specific clinical situations and the development of guidelines for replanning criteria are necessary before this method can be widely applied in routine clinical practice. They also envision CBCT-based dose calculation as an "extra benefit" for patients, potentially leading to reduced radiation exposure, treatment delays, and medical costs.

Summary updated

Abstract

CBCT-based dose calculations produced accuracy comparable to that of simulation CT. CBCT-based dosimetry can guide the decision to replan during the course of treatment.
BibTeX
@article{chen2017feasibility,
  author = {Shifeng Chen and Quynh‐Thu Le and Y. D. Mutaf and Wei Lü and E.M. Nichols and Byong Yong Yi and T. Leven and K Prado and W DˈSouza},
  title = {{Feasibility of <scp>CBCT</scp>‐based dose with a patient‐specific stepwise <scp>HU</scp>‐to‐density curve to determine time of replanning}},
  journal = {Journal of Applied Clinical Medical Physics},
  year = {2017},
  doi = {10.1002/acm2.12127},
}
Figure